DCPH Deciphera Pharmaceuticals, Inc.

36.07-0.94 (-2.54%)
Close: August 23, 2019

Quote

Previous Close
$36.07
Day Range
$35.98-$37.56
52 Week Range
$18.55-$42.99
Volume
526,601
Avg Volume
1,079,570
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$1.77B
Enterprise Value (EV)
$1.53B
PE Ratio
-
EV/EBITDA
-14.78
Price/Sales
-
Price/Book
6.32
PEG Ratio
0.79

Financials

Revenue
-
Gross Profit
-$317.00K
EBITDA
-$103.78M
EPS, ttm
-$3.31
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/7/2019 (74 days)
Debt to Equity
5%
Debt
$59.23M
Cash
$293.76M
Net Debt
-

Performance

Beta
1.81
200 Day Moving Avg
$24.65
50 Day Moving Avg
$25.07
52 Week Change
1.69%
YTD Change
57.91%
1 Month Change
64.63%
3 Month Change
52.39%
6 Month Change
25.46%
1 Year Change
1.69%
2 Year Change
34.16%
5 Year Change
34.16%

Share Count

Shares Outstanding
49.0M
Float
21.4M
Restricted Shares
27.6M
Restricted Shares, %
56.35%

Deciphera Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Steven L. Hoerter

Website: http://www.deciphera.com

Description: Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Employees: 114